Skip Navigation


NDT Advance Access originally published online on September 15, 2006
Nephrology Dialysis Transplantation 2006 21(12):3357-3361; doi:10.1093/ndt/gfl508
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/12/3357    most recent
gfl508v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Locatelli, F.
Right arrow Articles by Andrulli, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Locatelli, F.
Right arrow Articles by Andrulli, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

IgA nephritis: ACE inhibitors, steroids, both or neither?

Francesco Locatelli, Claudio Pozzi and Simeone Andrulli

Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy

Correspondence and offprint requests to: Professor Francesco Locatelli, Department of Nephrology and Dialysis, Ospedale A Manzani, via dell'Eremo 9, 23900 Lecco, Italy. Email: nefrologia@ospedale.lecco.it

Keywords: ACE inhibitors; angiotensin II receptor blockers; Cytotoxic drugs; IgA Nephritis; renal progression; steroids; treatment

The first 150 words of the full text of this article appear below.



   Introduction
 
Immunoglobulin A nephropathy (IgAN), a disease characterized by the predominant deposition of IgA in the glomerular mesangium, is the most common glomerulonephritis in the world. No more than 10% of all patients experience complete remission of the urinary abnormalities, and IgAN frequently progresses towards chronic renal impairment, leading to end-stage renal disease in about 25% of the patients within 20 years [1]. Should this nephropathy be treated? If so, what is the best therapy? And should all patients be treated with the same drugs? The real problem is that, although some progress has been made in our pathogenetic understanding, the disease is still largely unknown and no specific treatment is available.

Given the variability of the clinical and histological manifestations of IgAN, it is perhaps not surprising that there is still no general consensus about the treatment of IgAN [2], other than fully controlling hypertension possibly . . . [Full Text of this Article]



   What is the role of ACEIs and/or ARBs?
 


   Are corticosteroids necessary and safe?
 


   Are steroids alone always enough?
 


   What should be done in everyday clinical practice?
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
F. W. Ballardie
Quantitative Appraisal of Treatment Options for IgA Nephropathy
J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2806 - 2809.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
E. N. Wardle
IgA Nephritis--Ace inhibitors, steroids etc?
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1785 - 1785.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Locatelli, C. Pozzi, and S. Andrulli
Reply
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1785 - 1785.
[Full Text] [PDF]